Peripheral CXCR3+CD8+ TEM cells and APCs are reported to be independent predictors of response and PFS in patients with HCC treated with anti‐PD‐1 ICB.[8] Other non‐invasive biomarkers, such as levels of IL‐6 and TGF‐β,[9] AFP and CRP,[10] were reported relevant to the prognosis of HCC patients treated with ICIs. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.